Background/Aims Patients with concurrent type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) face elevated cardiovascular risks. However, optimal oral antidiabetic drug (OAD) selection for this population remains unclear.
Methods Using the Korean National Health Information Database, we conducted a target trial emulation comparing cardiovascular outcomes among patients with T2DM and MASLD (defined by fatty liver index ≥30) who initiated sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas with metformin. The primary outcome was major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.
Results Among 71,071 patients (331,726 person-years), SGLT2 inhibitor users experienced a significantly lower MACE risk compared to sulfonylurea users (adjusted subdistribution hazard ratio [aSHR], 0.44; 95% confidence interval [CI], 0.31–0.62). SGLT2 inhibitors also demonstrated a lower MACE risk compared to thiazolidinediones (aSHR, 0.61; 95% CI, 0.39–0.96) and DPP-4 inhibitors (aSHR, 0.59; 95% CI, 0.42–0.83). Cardiovascular mortality risk was notably reduced with SGLT2 inhibitors compared to sulfonylureas (aSHR, 0.13; 95% CI, 0.03–0.50), thiazolidinediones (aSHR, 0.19; 95% CI, 0.04–0.86), and DPP-4 inhibitors (aSHR, 0.22; 95% CI, 0.06–0.84). Mediation analysis revealed that MASLD regression accounted for 8.7% of the total cardiovascular benefit when comparing SGLT2 inhibitors to sulfonylureas.
Conclusions In patients with concurrent T2DM and MASLD, SGLT2 inhibitors demonstrated better cardiovascular outcomes compared to other OADs. These findings suggest that SGLT2 inhibitors may be the preferred OAD choice for cardiovascular risk reduction in this high-risk population.
Citations
Citations to this article as recorded by
Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan Clinica Chimica Acta.2026; 589: 121028. CrossRef
Background/Aims Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD). We conducted a target trial emulation study to evaluate whether GLP-1RA decreases the risk of liver and non-liver outcomes.
Methods Patients with T2D and MASLD initiating GLP-1RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) were included from 2013 to 2022 in Merative™ Marketscan® Research Databases. Primary outcomes included incidences of (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Inverse probability of treatment weighting was applied to balance baseline characteristics and Cox regression models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI).
Results In the intention-to-treat design, GLP-1RA, compared with DPP-4i, had a significantly lower incidence (per 1,000 person-years) of HCC (0.8 vs. 1.7; HR 0.53, 95% CI 0.39–0.71), of cirrhosis (29.3 vs. 32.9; HR 0.91, 95% CI 0.86–0.96), of CVD (57.2 vs. 73.9; HR 0.90, 95% CI 0.86–0.95), of CKD (4.5 vs. 6.8; HR 0.73, 95% CI 0.64–0.84), and of non-liver cancer (16.9 vs. 22.9; HR 0.82, 95% CI 0.77–0.89). In the per-protocol design, significant inverse associations for these study outcomes still were observed, with HR 0.60–0.77.
Conclusions In this emulated target trial of nationwide patients with T2D and MASLD, GLP-1RA use, when compared with DPP-4i, was associated with a significantly lower risk of liver and non-liver complications.
Citations
Citations to this article as recorded by
Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2026; 20(2): 292. CrossRef
Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus Jiwon Yang, Yeongseok Hwang, Jin-Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim Hepatology.2026;[Epub] CrossRef
Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel Diabetes, Obesity and Metabolism.2026; 28(7): 5704. CrossRef
Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic l Shio-Shin Jean, Chih-Cheng Lai Clinical and Molecular Hepatology.2026; 32(2): e163. CrossRef
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Chunyan Wang, Xu Han, Yinyan Li Clinical and Molecular Hepatology.2026; 32(2): e167. CrossRef
Correspondence to letter to the editor 1 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e231. CrossRef
Correspondence to letter to the editor 2 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e249. CrossRef
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e165. CrossRef
Correspondence to editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e219. CrossRef
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e267. CrossRef
GLP-1RA may open a new era for MASLD treatment: Editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target tria Ye Feng, Chengfu Xu Clinical and Molecular Hepatology.2026; 32(2): 924. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip Alimentary Pharmacology & Therapeutics.2026; 64(3): 356. CrossRef
GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes Xianhua Mao, Hong Fan, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen Hepatology.2026;[Epub] CrossRef
Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma Vanilla X. Zhang, Tiffany C.-Y. Yu, Yu M. Tsui, Irene O.-L. Ng Trends in Molecular Medicine.2026;[Epub] CrossRef
Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis Pedro Robson Costa Passos, Rodrigo Motta, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Roberto Cavalcante Venâncio, Guilherme Grossi Lopes Cançado, Amanda Adler, Jeremy F. Cobbold, Jeremy W. Tomlinson Diabetes Care.2026; 49(6): 1144. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026;[Epub] CrossRef
Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program Erik Almazan, Jonggi Choi, Tushar Kamath, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Tracey G. Simon, Raymond T. Chung American Journal of Gastroenterology.2026;[Epub] CrossRef
Association between hemoglobin glycation index and new-onset diabetes mellitus in individuals with chronic liver disease: Findings from a prospective cohort study using CHARLS data Yanyan Mao, Hui Kong, Li Wang, Fangyan Liao, Xiangwen Li Medicine.2026; 105(27): e49567. CrossRef
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study Yan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, Ying-Yi Qin, Hong-Ming Yu, Yu-Qiang Cheng, Gang Chen, Jia-Yi Wu, Yong-Yi Zeng, Yu-Fu Tang, Jian-Hua Rao, Feng-Min Zhang, Shi-Ye Yang, Gui-Ran Wang, Lin-Sen Ye, Ren Lang, Jian-Hua Lin, Yi-Tao Zheng, Ye-Fan Mao, Ho Gut.2026; : gutjnl-2026-338462. CrossRef
How Negative Controls Are Used in Pharmacoepidemiology: A Methodological Scoping Review of Real‐World Observational Studies of Glucagon‐Like Peptide‐1 Receptor Agonists Zhengxuan Li, Yinan Huang, Hua Chen, Jieni Li Pharmacoepidemiology and Drug Safety.2026;[Epub] CrossRef
Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai European Journal of Pharmacology.2025; 1005: 178088. CrossRef
Impaired Thyroid Hormone Sensitivity is Associated with Increased
Risk of Liver Fibrosis in Euthyroid Population: A Cross-Sectional Analysis of
NHANES Xingyu Yao, Kaiwen Xiao, Hein Ko Oo Hormone and Metabolic Research.2025; 57(09): 511. CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study” Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Assessing Nutritional Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease via Diverse Statistical Tools Yea-Chan Lee, Hye Sun Lee, Soyoung Jeon, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee Diabetes & Metabolism Journal.2026; 50(1): 178. CrossRef
Reduced skeletal muscle mass and elevated phase angle are linked to metabolic dysfunction-associated steatotic liver disease in Japanese males Satoko Tajirika, Takao Miwa, Masahito Shimizu, Mayumi Yamamoto Nutrition.2026; 146: 113118. CrossRef
Burden and Health System Challenges in MASLD Across East and Southeast Asia: A Narrative Review Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Wan‐Yu Wang, Shu‐Fen Liao, Ching‐Wen Chang Health Science Reports.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki Internal Medicine.2025; 64(9): 1296. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho JHEP Reports.2025; 7(9): 101477. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Impact of Continuous Nutritional Counseling on Liver Function and Body Composition in Patients with MASLD/MASH Shiho Asai, Naoto Kawabe, Akemi Ito, Teiji Kuzuya, Eizaburo Ohno, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yuka Ochi, Sayuri Miyaji, Sayaka Morisaki, Yoshiki Hirooka Kanzo.2025; 66(6): 222. CrossRef
Temporal Trends in Cardiovascular Mortality in Underlying Viral Hepatitis: A Retrospective Analysis of Gender, Racial/Ethnic, and Regional Disparities Wania Sultan, Haider Ashfaq, Hamza Ashraf, Ahmad Khan, Ayman Omair Hashmi, Muhammad Omar Larik, Maheen Zahid, Yasir Majeed, Pratik Bhattarai, Ashujot K. Dang, Ahmed Ali Aziz, Hafiz Muhammad Sharjeel Arshad JGH Open.2025;[Epub] CrossRef
Phocaeicola dorei
ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk Gut Microbes.2025;[Epub] CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef
From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease Andrea Pasta, Elena Formisano, Francesco Calabrese, Elisa Marabotto, Manuele Furnari, Giorgia Bodini, Maria Corina Plaz Torres, Livia Pisciotta, Edoardo Giovanni Giannini, Patrizia Zentilin Microorganisms.2025; 13(2): 241. CrossRef
Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto Clinical and Molecular Hepatology.2025; 31(Suppl): S182. CrossRef
In response to: Steatotic liver disease-know your enemies Michael H. Le, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2024; 30(2): 284. CrossRef
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma Lung-Yi Mak Journal of Liver Cancer.2024; 24(2): 145. CrossRef
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD.
Citations
Citations to this article as recorded by
FIB‐4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD Ya‐Chin Huang, Chih‐Wen Wang, Jiun‐Chi Huang, Po‐Cheng Liang, Ming‐Lun Yeh, Yi‐Yu Chen, Yi‐Hung Lin, Tyng‐Yuan Jang, Yu‐Ju Wei, Ming‐Yen Hsieh, Chao‐Kuan Huang, Hsu‐Han Chien, Chia‐Jen Wu, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Chia‐I Lin, Chung‐Fen Journal of Gastroenterology and Hepatology.2026; 41(1): 332. CrossRef
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yi‐Hung Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu Alimentary Pharmacology & Therapeutics.2026; 63(8): 1119. CrossRef
Serum mir-181a as a potential serological biomarker for metabolic dysfunction-associated fatty liver disease: A cross sectional study Ke-Gong Xiong, Jin-Feng Kong, Tai-Shun Lin, Qing-Biao Lin, Kun-Yu Ke Medicine.2026; 105(4): e47290. CrossRef
Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease Chieh Liu, Yi-Fen Shih, Chun-Jen Liu Clinical and Molecular Hepatology.2026; 32(2): 565. CrossRef
Metabolic biomarkers predict subclinical cardiac remodeling in obese individuals Mengjie Hu, Huawei Wang, Zixuan Mei, Cheng Gong, Lan Lan, Zixuan Ma, Binhao Zhang, Haomiao Fan, Yuqing Zhang, He Wang, Wanshun Chun, Dingyu Pan, Jianliang Zhou, Zhen Li Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis Hao-Chien Hung, Po-Jung Hsu, Yin Lai, Wei-Chen Lee, Chen-Fang Lee Annals of Hepatology.2026; : 102231. CrossRef
A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B Moon Haeng Hur, Terry Cheuk-Fung Yip, Seung Up Kim, Hyun Woong Lee, Han Ah Lee, Hyung-Chul Lee, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Hwi Young Kim, Yeon Seok Seo, Hyunjae Shin, Jeayeon Park, Yunmi Ko, Yo Journal of Hepatology.2025; 82(2): 235. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?” Moon Haeng Hur, Jeong-Hoon Lee Journal of Hepatology.2025; 82(3): e143. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure Kai-Chun Chang, Tung-Hung Su, Cho-Kai Wu, Shang-Chin Huang, Tai-Chung Tseng, Chun-Ming Hong, Shih-Jer Hsu, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao European Journal of Heart Failure.2025; 27(3): 512. CrossRef
Metabolic dysfunction-associated steatotic liver disease and its associated health risks Xia-Rong Liu, Szu-Ching Yin, Yi-Ting Chen, Mei-Hsuan Lee Journal of the Chinese Medical Association.2025; 88(5): 343. CrossRef
Fatty Liver and Hyperuricemia in Workers: Combined Effects on Metabolic Dysfunction and the Role of Lifestyle Factors Jui-Hua Huang, Ren-Hau Li, Hon-Ke Sia, Feng-Cheng Tang Metabolites.2025; 15(5): 318. CrossRef
Application of insulin resistance score in type 2 diabetes mellitus complicated with fatty liver and liver fibrosis Shaojie Duan, Mengdie Chen, Jie Chen, Yaojian Shao, Xiaolong Jin, Chaohui Wang, Ping Feng, Xiaosheng Teng, Zhenjun Yu European Journal of Gastroenterology & Hepatology.2025; 37(10): 1155. CrossRef
The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace Biomedicine & Pharmacotherapy.2025; 190: 118375. CrossRef
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer Pin-Nan Cheng, Ming-Lung Yu Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef
MAFLD: from a disease framework to patient care Mohammed Eslam, Jacob George Hepatology International.2024; 18(S2): 823. CrossRef
Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus Wei-Fan Hsu American Journal of Cancer Research.2024; 14(4): 1914. CrossRef
The unfolded features on the synchronized fashion of gut microbiota and Drynaria rhizome against obesity via integrated pharmacology Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Dong Joon Kim, Ki-Tae Suk Food Chemistry.2024; 460: 140616. CrossRef
High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang Scientific Reports.2024;[Epub] CrossRef
MASLD: an emerging factor in the pathophysiology and clinical management of ICC Zong-Long Li, Jia-Lu Chen, Yue Tang, De-Long Qin, Zhao-Hui Tang Hepatoma Research.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study Ryuk Jun Kwon, Yohwan Lim Frontiers in Endocrinology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study Woo-Young Shin, Eun Seok Kang, Yun Hwan Oh, Meng Sha, Qiang Xia, Seogsong Jeong, Yoosun Cho BMC Gastroenterology.2025;[Epub] CrossRef
Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi PLOS One.2025; 20(6): e0323880. CrossRef
GH Replacement Therapy Is Associated with Ameliorations in Body Composition and Fatty Liver Index in Patients with Adult-Onset Isolated GH Deficiency Elena Gangitano, Rebecca Rossetti, Giusy Simeone, Mariaignazia Curreli, Orietta Gandini, Stefania Mariani, Carla Lubrano Livers.2025; 5(4): 56. CrossRef
Prognostic value of coronary artery calcium score for the prediction of atherosclerotic cardiovascular disease in participants with suspected nonalcoholic hepatic steatosis: Results from the multi-ethnic study of atherosclerosis Keishi Ichikawa, Spencer Hansen, Venkat S. Manubolu, Leili Pourafkari, Hooman Fazlalizadeh, Jairo Aldana-Bitar, Lisa B. VanWagner, Srikanth Krishnan, Matthew J. Budoff American Heart Journal.2023; 265: 104. CrossRef
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca Diagnostics.2023; 13(21): 3316. CrossRef
Does metabolic dysfunction-associated steatotic liver disease affect the ocular circulation? Nihat Aydın, Mustafa Capraz, Burcu Akman, Seyma Nur Altınok, Melek Tufek, Caner Kara Photodiagnosis and Photodynamic Therapy.2026; 57: 105334. CrossRef
Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018 Chaojie Yu, Chen Qiu, Qian Zhang, Wenrui Wang, Siqi Liu, Zhenjing Jin Cardiovascular Diabetology.2026;[Epub] CrossRef
Association between nonalcoholic fatty liver disease and stroke: a cross-sectional study Shuai Zhou, Ge Mang, Hu Zhou, Shuoqi Zhang, Adam A. Dmytriw, Baocheng Gao, Shengquan Huang, Shuaifeng Yang, Lide Jin, Yongfa Zhang, Jiaqi Jin, Tianhua Li International Journal of Surgery.2026; 112(5): 11170. CrossRef
No association between steatotic liver disease and atherosclerosis among Brazilian
travestis
and transgender women: a cross-sectional study
Rodrigo de Carvalho Moreira, Emilia Moreira Jalil, Hugo Perazzo, Marcelo Cunha, Eduarda Grinsztejn, Isabele Moura, Mônica Derrico, Laylla Monteiro, Biancka Fernandes do Nascimento, Ronaldo Ismério Moreira, Valdiléa Gonçalves Veloso, Beatriz Grinsztejn, Sa International Journal of Transgender Health.2026; : 1. CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef
Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease Jihye Lim, Hyunji Sang, Ha Il Kim JHEP Reports.2023; 5(6): 100721. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.
Citations
Citations to this article as recorded by
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu Clinical Pharmacology & Therapeutics.2026; 119(2): 336. CrossRef
Cardiovascular outcomes of intensive blood pressure control in patients with and without metabolic dysfunction-associated fatty liver disease: post hoc analysis of the CRHCP trial Songyue Liu, Yangzhi Yin, Hongmei Yang, Lufan Sun, Jun Wang, Ying Zhou, Lin Guan, Liying Xing, Ziyi Xie, Ning Ye, Chuan Yang, Wei Miao, Shiyu Zhou, Yao Yu, Zhi Li, Xiangyu Tan, Caiyu Zhang, Chenhua He, Yueting Liu, Yifei Chen, Guozhe Sun, Xiaofan Guo BMC Medicine.2026;[Epub] CrossRef
Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar Aisha Al-Khinji, Dhafer Malouche, Noof Al-Thani, Azza Mustafa, Jazeel Abdulmajeed, Mohamed Ghaith Al-Kuwari Frontiers in Medicine.2026;[Epub] CrossRef
Effect of intermittent fasting on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease Qinhan Liu, Ling Zhang, Yaomin Wang, Jun Li, Yaling Li Clinics and Research in Hepatology and Gastroenterology.2026; 50(7): 102875. CrossRef
Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction Ángel Arturo López-González, Emilio Martínez-Almoyna Rifá, Hernán Paublini Oliveira, Cristina Martorell Sánchez, Pedro Juan Tárraga López, José Ignacio Ramírez-Manent Life.2025; 15(1): 116. CrossRef
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim Clinical and Molecular Hepatology.2025; 31(1): 74. CrossRef
Non alkolik yağlı karaciğer hastalığı ile kafein alımı arasındaki ilişki İzel Akkaya, İlknur Gökçe Yıldırım Sağlık Profesyonelleri Araştırma Dergisi.2025; 7(1): 47. CrossRef
Advances in humanoid organoid-based research on inter-organ communications during cardiac organogenesis and cardiovascular diseases Baoqiang Ni, Lingqun Ye, Yan Zhang, Shijun Hu, Wei Lei Journal of Translational Medicine.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Investigating the Mechanisms of Lycii fructus in Treating Nonalcoholic Fatty Liver Disease and Diabetes Comorbidity Through Network Pharmacology and Molecular Dynamics Peng Sun, Jiahui Song, Yang Liu, Xiujing Li, Yiming Zhang, Yuxing Zhou, Wei Gong Food Science & Nutrition.2025;[Epub] CrossRef
Increased BMD in SLD Patients Without Advanced Hepatic Fibrosis: Evidence From the NHANES 2017–2020 Database Tianhao Wu, Lu Li, Yayuan Mei, Peizhen Lv, Jiawei Cui, Lin Liu, Yuemin Nan, Ang Li, Yu-Chen Fan Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Extrahepatic Comorbidities Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease; A Tertiary Hospital Experience Masoudreza Sohrabi, Mozhdeh Mosalli, Parvin Hassanzadeh, Somayeh Bahrami, Mahmoodreza Khoonsari, Hossein Ajdarkosh, Farhad Zamani Middle East Journal of Digestive Diseases.2025; 17(2): 96. CrossRef
Causal Relationship between Psoriasis and Non-Alcoholic Fatty Liver Disease: A Bidirectional Two-Sample Mendelian Randomization Study 恒 杨 Advances in Clinical Medicine.2024; 14(04): 101. CrossRef
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research E. V. Biryukova Meditsinskiy sovet = Medical Council.2024; (6): 72. CrossRef
Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi BMC Endocrine Disorders.2024;[Epub] CrossRef
Masquerading Spleen: A Perplexing Case of Intrahepatic Splenosis Mimicking Hepatocellular Carcinoma Noriko Ikeda, Yujo Kawashita, Masaki Tateishi, Takashi Ueda, Junzo Yamaguchi, Yasuo Washida, Yoichi Hachitanda Cureus.2024;[Epub] CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(2): 358. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease Maryam K. Ibrahim, Tracey G. Simon, Mary E. Rinella Clinics in Liver Disease.2023; 27(2): 251. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future Jung Hwan Yu, Han Ah Lee, Seung Up Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Diabetes and cirrhosis: Current concepts on diagnosis and management Laurent Castera, Kenneth Cusi Hepatology.2023; 77(6): 2128. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
Polycystic ovary syndrome in pediatric obesity and diabetes Elena DONDI, Maria TUFANO, Maria C. VIGONE, Laura LUCACCIONI, Gabriella POZZOBON, Graziamaria UBERTINI, Enza MOZZILLO, Maurizio DELVECCHIO Minerva Pediatrics.2022;[Epub] CrossRef
Mouse liver injury induces hepatic macrophage FGF23 production Pradeep Kumar, Yunshan Liu, Yang Shen, Jacquelyn J. Maher, Francesca Cingolani, Mark J. Czaja, Matias A Avila PLOS ONE.2022; 17(3): e0264743. CrossRef
New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Life.2022; 12(8): 1189. CrossRef
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Clinical and Molecular Hepatology.2022; 28(4): 725. CrossRef
Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Biomedicines.2022; 10(10): 2375. CrossRef
Intestinal microbiota in the treatment of metabolically associated fatty liver disease Ji-Shuai Wang, Jin-Chun Liu World Journal of Clinical Cases.2022; 10(31): 11240. CrossRef
A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review Chowdhury F Zaman, Jakia Sultana, Proma Dey, Jui Dutta, Sadia Mustarin, Nuzhat Tamanna, Aditi Roy, Nisha Bhowmick, Mousumi Khanam, Sadia Sultana, Selia Chowdhury, Farjana Khanam, Md Sakibuzzaman, Priyata Dutta Cureus.2022;[Epub] CrossRef
The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials Carmine Izzo, Monica Annunziata, Giuseppe Melara, Roberta Sciorio, Marcello Dallio, Mario Masarone, Alessandro Federico, Marcello Persico Nutrients.2021; 13(3): 933. CrossRef
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease Ho Soo Chun, Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Cachexia, Sarcopenia and Muscle.2021; 12(5): 1168. CrossRef
The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation‐wide Cohort Study Yewan Park, Dong Hyun Sinn, Joo Hyun Oh, Myung Ji Goh, Kyunga Kim, Wonseok Kang, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Geum‐Youn Gwak Hepatology.2021; 74(6): 2988. CrossRef
Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus Kiyoung Lim, Minkyu Kang, Junggil Park Nutrients.2021; 13(10): 3400. CrossRef
Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung Diagnostics.2021; 11(12): 2233. CrossRef
Non‑alcoholic fatty liver disease and hematologic manifestations (Review) Vlad Pădureanu, Dalia Dop, Alice Drăgoescu, Rodica Pădureanu, Anca Mușetescu, Laurențiu Nedelcu Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression Marcello Dallio, Moris Sangineto, Mario Romeo, Rosanna Villani, Antonino Davide Romano, Carmelina Loguercio, Gaetano Serviddio, Alessandro Federico International Journal of Molecular Sciences.2021; 22(1): 436. CrossRef
Nutraceutical correction in the complex non-drug treatment of metabolic syndrome L.G. Agasarov, T.V. Apkhanova, V.N. Sergeev, A.D. Fesun, M.M. Krukova, V.A. Vasilyeva, D.B. Kulchitskaya, T.V. Konchugova, G.A. Puzyreva, M.Yu. Yakovlev Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul'tury.2021; 98(4): 25. CrossRef
Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events? Emily N. W. Yeung, Philipp Treskes, Sarah F. Martin, Jonathan R. Manning, Donald R. Dunbar, Sophie M. Rogers, Thierry Le Bihan, K. Ann Lockman, Steven D. Morley, Peter C. Hayes, Leonard J. Nelson, John N. Plevris Lipids in Health and Disease.2015;[Epub] CrossRef
Prevalence of Metabolic Syndrome and Related Risk Factors of Elderly Residents in Andong Rural Area 2. Based on the Biochemical Measurements and Nutrient Intakes Hye-Sang Lee, Chong-Suk Kwon Journal of the Korean Society of Food Science and Nutrition.2010; 39(10): 1459. CrossRef
First
Prev
